Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immune checkpoint inhibitors have changed how cancer is treated. As of February 2022, six immune checkpoint inhibitors had been approved, with Keytruda and Opdivo accounting for the majority of global sales. Here, the impact of the differences in commercial success between Keytruda and Opdivo is reviewed by analyzing inter-organizational deals since their launch in 2014. Both showed a correlation between the cumulative number of indications and product sales trends, the latter crossing from 2017 to 2018. Differences in sales were due to different approaches to life cycle management by inter-organizational deals and drug development strategies, the key to commercial success.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2022.103390 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognosis and Toxicity Stratified by Best Tumor Burden Change in Japanese Patients With Advanced Melanoma Treated With First-Line Programmed Cell Death Protein 1 Monotherapy.
J Dermatol
September 2025
Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan.
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in patients with advanced malignant melanoma (MM). However, more than half of patients receiving anti-programmed cell death protein-1 (PD-1) antibody monotherapy still fail to respond, with response rates varying by race and melanoma subtype. Additionally, immune-related adverse events (irAEs) remain a major concern.
View Article and Find Full Text PDFSuccessful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report.
IJU Case Rep
September 2025
Department of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.
Introduction: Enfortumab vedotin plus pembrolizumab (EV + ) shows high efficacy in metastatic urothelial carcinoma (mUC), potentially increasing tumor lysis syndrome (TLS) risk.
Case Presentation: A 64-year-old man with mUC underwent surgery and adjuvant nivolumab after neoadjuvant chemotherapy. Five months post-surgery, EV + was initiated for recurrence with distant metastasis.
Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer.
Cancer Treat Rev
August 2025
Department of Otorhinolaryngology, Head & Neck Surgery, University of Fukui Hospital, Japan.
Aim: To critically review the emerging evidence from two randomised trials-KEYNOTE-689 and NIVOPOSTOP-on perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma, and to elucidate how these positive results may redefine the current and future treatment paradigms.
Methods: We conducted a narrative review comparing the design, patient populations, treatment protocols, and outcomes of KEYNOTE-689 and NIVOPOSTOP. Data sources included ClinicalTrials.
Background: Patients with BRAF wild type (wt) metastatic melanoma who exhibit primary resistance to immune checkpoint inhibitors (ICI) face a poor prognosis. Chemotherapy has been shown to induce genetic mutations, modify the tumor microenvironment and microbiome, and influence immune system activity.
Objectives: This prospective multicenter phase II trial investigates whether two applications of an alkylating agent (dacarbazine/DTIC) can sensitize ICI non-responsive patients with metastatic melanoma to the same checkpoint inhibitor regime.
Survival patterns after perioperative treatment escalation and cystectomy for synchronous oligometastatic bladder cancer (M1a/M1b) - a population-based series.
Scand J Urol
September 2025
Department of Urology, Skåne University Hospital, Malmö, Sweden; Institution of Translational Medicine, Lund University, Malmö, Sweden.
Background: The role of cystectomy in synchronous oligometastatic bladder cancer is unclear.
Objective: To describe a population-based consecutive cohort with primary oligometastatic bladder cancer (M1a or M1b) treated with curative intent. Methods: Twenty consecutive patients with primary stage M1a or M1b bladder cancer subjected to induction chemotherapy and radical cystectomy 2013-2024 in the Southern healthcare region were identified in the Swedish National Register for Urinary Bladder Cancer.